| Literature DB >> 33851270 |
Alberto Aiolfi1, Marta Cavalli2, Simona Del Ferraro2, Livia Manfredini2, Francesca Lombardo3, Gianluca Bonitta3, Piero Giovanni Bruni2, Valerio Panizzo3, Giampiero Campanelli2, Davide Bona3.
Abstract
PURPOSE: To examine the updated evidence on safety, effectiveness, and outcomes of the totally extraperitoneal (TEP) versus the laparoscopic transabdominal preperitoneal (TAPP) repair and to explore the timely tendency variations favoring one treatment over another.Entities:
Keywords: Chronic pain; Inguinal hernia; Laparoscopic transabdominal preperitoneal repair (TAPP); Recurrence; Totally extraperitoneal repair (TEP); Trial sequential analysis
Mesh:
Year: 2021 PMID: 33851270 PMCID: PMC8514389 DOI: 10.1007/s10029-021-02407-7
Source DB: PubMed Journal: Hernia ISSN: 1248-9204 Impact factor: 4.739
Fig. 1The Preferred Reporting Items for Systematic Reviews and meta-analysis checklist (PRISMA) diagram
Demographic and clinical characteristics of patients undergoing laparoscopic trans abdominal pre-peritoneal (TAPP) and totally extra peritoneal (TEP) repair
| Author | Country | Surgical procedure | No. patients | Age (years) | Gender (male) | Type of hernia | Type of mesh | Follow-up (mos) |
|---|---|---|---|---|---|---|---|---|
| Schrenk et al. [ | Australia | TAPP/TEP | 28/24 | 39.1 ± 14.3 42.3 ± 11.9 | 24/22 | Indirect: 19/18, Direct: 9/6 | Polypropylene mesh (TAPP: SurgiPro®, Auto Suture®; TEP: SurgiPro®) | nr |
| Dedemadi et al. [ | Greece | TAPP/TEP | 24/26 | 65 (28–92) | nr | Nyhus class II 14/16, IIIA 7/8, IIIC 3/2 | TAPP: nr | 30 ± 1 |
| TEP: non absorbable mesh | ||||||||
| Gunal et al. [ | Turkey | TAPP/TEP | 39/40 | 25.7 ± 1 22.3 ± 0.6 | nr | Nyhus class: I, II, IIIA, IIIB | Polypropilene mesh (6 × 12 cm) | nr |
| Butler et al. [ | USA | TAPP/TEP | 22/22 | nr | nr | nr | Polypropylene mesh | 1 |
| Pokorny et al. [ | Austria | TEP/TAPP | 36/93 | 49 (19–73) 49 (21–78) | 35/86 | nr | Polypropylene mesh | 36 |
| Zhu et al. [ | China | TAPP/TEP | 20/20 | 62.3 ± 12 60.2 ± 9.7 | 19/20 | nr | nr | nr |
| Hamza et al. [ | Egypt | TAPP/TEP | 25/25 | 36.7 ± 12 34.9 ± 13 | 25/25 | Nyhus class I–III | nr | 24 |
| Krishna et al. [ | India | TEP/TAPP | 53/47 | 47.8 ± 16 51.3 ± 13.8 | 52/47 | Indirect: 37/41, Direct: 26/18 | Heavyweight polypropilene mesh (10 × 15 cm); preshaped 3Dmax polypropylene mesh | 30 |
| Gong et al. [ | China | TAPP/TEP | 50/52 | 56 ± 10 57 ± 9 | 50/52 | Indirect: 35/37, Direct: 9/11, Both: 6/4 | TAPP: polypropylene mesh (8.5 × 15 cm) | 16 ± 8 |
| TEP: Bard® 3Dmax (8.5 × 13 cm) | ||||||||
| Mesci et al. [ | Turkey | TAPP/TEP | 25/25 | 48.2 48.4 | nr | Indirect: 12/12 Direct: 8/7 Both: 5/7 | nr | nr |
| Wang et al. [ | China | TAPP/TEP | 84/84 | 48.2 ± 13.2 52.1 ± 17.4 | 70/71 | Indirect: 77/73, Direct: 6/8, Femoral: 1/3 | TAPP: vypro II mesh (12 × 15 cm) | 16 ± 7 |
TEP: vypro II mesh (10 × 15 cm) | ||||||||
| Bansal et al. [ | India | TEP/TAPP | 160/154 | 50.7 ± 17.3 43.4 ± 16.4 | nr | nr | Preshaped 3Dmax polypropylene mesh large size (Bard ®, 10.8 × 16 cm); Flat heavyweight polypropylene mesh (size 15 × 10 cm); Lightweight polypropylene mesh (Prolene soft, Ethicon®, 15 × 10 cm) | 30 ± 14 |
| Jeelani et al. [ | India | TAPP/TEP | 30/30 | 48.2 ± 13.3 46.7 ± 13 | 29/30 | nr | Polypropilene mesh (10 × 15 cm) | 24 |
| Ciftci et al. [ | Turkey | TEP/TAPP | 30/31 | 44.4 ± 15.3 45.7 ± 11.1 | 26/26 | Indirect: 20/20, Direct: 3/4, Both 7/7 | Polypropilene mesh (15 × 8 cm) | 3 |
| Sharma et al. [ | India | TAPP/TEP | 30/30 | 49.4 49 | 59 | Indirect: 33/28, Direct: 27/32 | Polypropilene mesh (10 × 12 cm) | 1 |
Data are reported as numbers, mean ± standard deviation, median (range)
mos months, nr not reported
Fig. 2a–c Forrest plot (a), funnel plot (b) and trial sequential analysis (c) for postoperative hernia recurrence
League table
| Categorical outcomes | RR (95% CI) | No. studies | No. patients | |
|---|---|---|---|---|
| Hernia recurrence | 0.83 (0.35–1.96) | 0.0% (0.0–0.0%) | 11 | 1040 |
| Hernia recurrence (> 12-month follow-up) | 0.95 (0.65–2.34) | 0.0% (0.0–0.0%) | 7 | 805 |
| Chronic pain | 1.51 (0.54–4.22) | 0.0% (0.0–44%) | 7 | 873 |
| Chronic pain (> 12-month follow-up) | 1.42 (0.63–3.84) | 0.0% (0.0–26%) | 6 | 821 |
| Haematoma | 1.19 (0.47–2.97) | 0.0% (0.0–53%) | 10 | 714 |
| Seroma | 1.24 (0.75–2.07) | 0.0% (0.0–32%) | 8 | 932 |
| Wound infection | 0.45 (0.17–1.17) | 0.0% (0.0–0.0%) | 9 | 916 |
Each row represents a specific outcome. Values in each column represent the relative effect for the comparison TEP vs, TAPP. Values are expressed as Risk Ratio (RR), weighted mean difference (WMD), and 95% confidence intervals (95% CI)
I2 Heterogeneity, VAS Visual Analog Scale
Fig. 3a–b Forrest plot (a) and trial sequential analysis (b) for postoperative chronic pain